LSTA

Lisata Therapeutics has experienced several significant stock events in the past six months. The company entered into a binding term sheet to be acquired by Kuva Labs, Inc., but the acquisition has faced delays. Lisata Therapeutics mutually terminated its license agreement with Qilu Pharmaceutical, regaining rights for certepetide in the Greater China region. The company reported its Q3 2025 financial results, highlighting cash and investments, operating expenses, and positive data from clinical studies. Lisata Therapeutics' stock was trading at $1.86 on January 1st, 2026, and has since increased by 69.4% to $3.15 as of May 8, 2026.